Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus fermentum VRI 003
- Development stage
- Unknown
- Lead developer
- Bioxyne
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus fermentum VRI 003, also known by the brand name PCC®, is a probiotic biologic developed by Probiomics Ltd. It is a specific strain of the Gram-positive bacterium *Lactobacillus fermentum*. This probiotic has been clinically studied for its ability to modulate the immune system. Research has shown its potential benefits in improving the severity of atopic dermatitis in children and reducing the incidence and duration of respiratory and gastrointestinal illnesses, particularly in athletes. [1, 3, 7] The proposed mechanism of action involves the modulation of the mucosal immune system. [2] The strain exhibits mannose-specific adhesion to Peyer's patches in the gut, which is believed to influence cytokine production (such as increasing interferon-gamma) and enhance mucosal immunity. [10, 2] It is administered orally, typically in freeze-dried powder form within gelatin capsules.
- Brand names
- PCCProBio PCCPrograstrim
- Other names
- Lactobacillus fermentum VRI-003
Beyond the preview
Go deeper on lactobacillus fermentum VRI 003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus fermentum VRI 003.